MiCheck® Test

We have developed a prostate cancer blood test called MiCheck®. A series of clinical trials have shown it has superior specificity compared to prostate cancer blood tests that are available today.

MiCheck® fills the need for a test to assist physicians to decide whether or not a patient should proceed to a prostate biopsy following a high PSA reading.

  • More specific than a PSA test – so a urologist can tell if a biopsy is really needed.
  • Patients and their physicians will have confidence about what to do next.
  • Patients who should get treatment for prostate cancer will get it sooner, and men whose MiCheck® results are negative can be monitored regularly.

That means:

  • Fewer invasive tests – better for patients
  • Lower healthcare costs – better for healthcare budgets and insurers
  • More targeted testing– better for urologists and patients due to less patient anxiety, more efficient patient care, fewer infection risks

We are currently undertaking a US-based trial prior to its market launch.

%

PSA

%

MiCheck®

MiltuximabTM for Therapeutic & Imaging Applications

Our patented antibodies target Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors.
We are examining multiple mechanisms of action including:

  • Radio immunotherapy
  • Antibody drug conjugates
  • Immune cell engagement and activation

We have commenced a first in-human trial using Miltuximab, our anti-GPC-1 monoclonal antibody (ANZCTR registry).

In October 2016 Minomic announced the start of our first in-human trial using Miltuximab conjugated to the radioactive isotope 67Gallium. We have now dosed a total of 6 patients with no adverse reactions whatsoever.

A Decade of Achievements

N

2007

Minomic formed to pursue opportunity in biomarkers based on MIL-38 monoclonal antibody

N

2009

Showed antibody binding to prostate cancer cells

N

2011

Received Venture Capital funding for commercialization

N

2014

Clinical validation studies for MiCheck® commenced
N

2016

Awarded Accelerating Commercialization grant to further product development
N

2016

Commenced First-in-Human trial of Miltuximab™
N

2017

Commenced MiCheck® Prospective Trial

2015 Eureka Prize

Excellence in Interdisciplinary Scientific Research

Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.

Find Out More Information

  • About our highly effective prostate cancer blood test >More
  • About our groundbreaking first in human trial of our novel cancer target >More
  • About how your company and Minomic could partner to deliver better prostate cancer diagnostics or therapeutics >More 

9 + 11 =

Address
Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia

Phone
International +612 9850 4000
In Australia 02 9850 4000
Compare your time zone with Sydney here

Email
info@minomic.com

Finding Us
We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

Headquarters of Minomic